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ABSTRACT: 
Background:  The availability and use of drugs with demonstrable efficacy in psychiatric disorders has grown since the late 
1950s. 10% to 15% of prescriptions written are for medications intended to affect mental processes—to sedate, stimulate or 
otherwise modify mood, thinking or behavior. 
Aim & objective: This study was carried out to evaluate the outcome of a SSRI, fluoxetine on memory functions in patients of 
two different age groups with minor mental illnesses, on long term administration. For this study, patients attending psychiatry 
OPD in Govt. Stanley medical college & hospital were included and simple subjective tests were carried out to evaluate memory 
functions. 
Materials and Methods: 
Memory functions were evaluated using the Wechsler memory scale which consists of seven subsets. Patient’s memory was 
evaluated before treatment, then at the end of 15 days and finally at the end of one month after administration of fluoxetine. 
Statistical analysis was carried out using Wilcoxon signed-rank test. 
Results & conclusion: The results of this study reveal that there was no deterioration in memory functions at first follow-up and 
they remain the same up to the end of one month. Rather it was observed that there was improvement in memory functions. So, 
final score of the parameters is because of the resultant activity of direct drug action and improvement in the underlying disease. 
Keywords:  Wechsler memory scale, fluoxetine, anti depressants. 
 
INTRODUCTION: 
The availability and use of drugs with demonstrable 
efficacy in psychiatric disorders has grown since the 
late 1950s to the point that 10% to 15% of prescriptions 
written in  are for medications intended to affect mental 
processes—to sedate, stimulate or otherwise modify 
mood, thinking or behavior. Antidepressants are 
commonly used medications in many psychiatric 
conditions like depression (42.72%), anxiety disorders 
like obsessive compulsive disorder, panic attack, 
psychosomatic disorders and various phobias (11.89%), 
pain (10.44%), insomnia (10.19%) and 
bipolardisorder(3.16%)
1
. Antidepressants like 
fluoxetine and other Selective serotonergic reuptake 
inhibitors (SSRIs) are shown to improve memory 
functions in some studies
2
 while memory parameters 
were found to decline in some other studies. Fluoxetine 
and Fluvoxamine were the first widely used selective 
serotonin reuptake inhibitors. The SSRIs are agents of 
choice in obsessive-compulsive disorder, as well as in 
possibly related syndromes of impulse dyscontrol or 
obsessive preoccupations, including compulsive 
gambling, trichotillomania, bulimia (but usually not 
anorexia nervosa), and body dysmorphic disorders. 
Antidepressants are widely used by ambulant patients, 
including geriatric population. So complete and 
quantitative evaluation of its outcome on memory 
functions will helps in making choice of the drug. 
Therefore this study was carried out to evaluate the 
outcome of long-term administration of a commonly 
prescribed SSRI, fluoxetine on memory function in two 
different age groups with minor psychiatric disorders 
using a simple scale to assess the memory functions. 
Aim:  To study the effect of fluoxetine on memory 
functions.  
Objective:     To study the effect of fluoxetine on 
memory functions in two different age groups (between 
15 &45; 46 and 60) 
MATERIALS & METHODS: 
 Study design- Prospective observational study 
 Study period- july 2013- jan 2014 
Study duration- One month/ patient 
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Place of study- Dept. of Psychiatry, Stanley medical 
college 
Study population- 50patients in each group 
Selection criteria: 
A) Inclusion criteria:  
 Both sex with age group  between 15  and 60 yrs 
 Patients with whom rapport can be established/ 
minor illness 
 Patients who can read and write in Tamil( native 
languge) 
 Patients with mild depression, anxiety, obsessive 
compulsive disorder, phobia and psychosomatic 
disorders who were prescribed fluoxetine were 
included 
 Patients who had given informed consent to 
participate in this study. 
B) Exclusion criteria: 
 Patients below 15 yrs and above 60 yrs 
 Patients with major psychiatric illness 
 Patients on other centrally acting drugs which may 
impair memory like sedatives, antipsychotics 
 Patients with serious systemic disorders like HIV, 
TB,HTN,DM 
 Patients who were on any other antidepressants at 
the time of enrollment to the study. 
 Pregnant and lactating women  
 Not willing to participate. 
 
Those patients who were willing to participate in the 
study were divided into two groups according to their 
age group  
   Group A- 50 patients, between15 and 45 years of 
age 
  Group B- 50 patients, between 46 and 60 years of 
age        
The aim, procedure of the study and the scale used to 
assess memory functions were explained to the patients. 
Study was conducted only after obtaining approval from 
Institutional ethics committee. Patients were asked 
questions related to the study, after explaining about the 
study in their own language. Only patients who were 
willing to participate and give informed consent were 
included. Written informed consent was obtained and 
patient's personal data like name, age, hospital number, 
educational status, occupation, mother tongue were 
noted at the first visit. Also symptoms, illness duration, 
past drug history and family history were also noted. A 
note of the diagnosis and treatment prescribed was 
recorded in the Performa at each visit. Adverse drug 
reaction and clinical progress observed by investigator 
or reported by the patient was also recorded in the pro 
forma. 
Wechsler memory scale was employed to assess the 
memory functions of the study patients. Baseline 
memory evaluation is done on 0 day before starting 
therapy, then at the end of 15days and then finally at the 
end of 1month of drug therapy. Diagnosis of case and 
dosage given are recorded. All patients are started with 
20mg fluoxetine. 
Tests:  The Wechsler memory scale was employed to 
assess the memory function of patients. It consists of 
seven subsets. Each has a maximum score of 6, 5, 
9,15,23,14 and the score for the last subset varies6. The 
tests are as follows: 
1. Personal and present memory:  It consists of six 
simple questions relating to personal and present 
information. 1 point for each correct response 
2. Orientation: It consists of five questions. 1 point 
for each correct response 
3. Mental control: This consist of 3 subsets with a 
maximum of  3 points for each and the total 
maximum score is 9 
4. Immediate recall: This was evaluated by the test 
of digit span forward and backward repetition. The 
maximum score is 15 
5. Logical memory:  A passage is read and the 
patient is asked to repeat the same passage. 
Verbatim is recorded and the maximum score is 23. 
6. Visual reproduction:  3 cards with geometrical 
picture are given and the patient is asked to draw 
the same. The maximum score is 14 
7. Associate learning:  Verbal retention for both 
similar and dissimilar pairs was assessed. Patients 
were allowed up to three trials in this test. 1 point 
for each correct response. Dissimilar pairs were 
considered as difficult and similar pairs were 
considered as easy. Net scoring will be sum of 
subject’s credits on easy association divided by 2 
and credits on difficult association. 
RESULTS:    
Data was statistically analyzed and compiled.  
Statistics - Wilcoxon Signed Rank Test using SPSS 
version 15.2. 
Patients were divided into two groups based on their 
age.  
 Sex distribution does not show any major 
difference between two groups.  
 All subsets of memory function tests were found 
not to deteriorate but rather improve at the first and 
second follow up in both the study groups and the p 
value is highly significant. (<0.001) 
 The improvement in memory functions were to the 
same level in both the groups at the end of 15 days 
and at the end of 1 month (>0.05) 
 No patient in either group complained of any sort 
of serious adverse effects. 
The mean memory score of each subtest in both the 
groups was tabulated as shown below.
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Table 1: Mean memory score obtained in both the groups at the baseline; end of 15 days & at the end of one 
month 
 
  Subtest 
               Group I ( 15-45yrs) Group II( 46-60yrs) 
Baseline  15 days 1 month Baseline 15 days 1 month 
Personal& Present memory(6)    5.80   5.88   5.96
* 
  5.84    5.92   6.00
* 
Orientation(5)  4.84   5.00
* 
  5.00   4.84   5.00
* 
  5.00 
Mental control (9)   6.04   6.88
*** 
  7.40
*** 
  5.88   6.68
*** 
  7.36
*** 
Immediate Recall (15) 10.52  11.44
*** 
 12.48
*** 
 9.96  10.88
*** 
 11.68
*** 
Logical Memory(23)  18.12  18.76
*** 
 19.52
*** 
17.84  18.60
*** 
 19.28
*** 
Visual  Reproduction (14)   9.68  10.48
*** 
 11.40
*** 
 9.60 10.48
*** 
 11.24
*** 
Associate Learning   11.60  12.36
*** 
 13.12
*** 
 11.40  12.12
*** 
12.96
*** 
  
 
 
Figure 1: showing Effect of fluoxetine on memory and cognition subtests in Group A 
PPM – present & past memory       MC – Mental control             IR – Immediate recall 
    LM- Logical memory                     VR – visual reproduction       AL – Associate learning 
 
 
Figure 2: showing, Effect of fluoxetine on memory and cognition subtests-Group B 
 
DISCUSSION: 
Cognitive function is the brain’s ability to acquire 
process, integrate, store, and retrieve information. It 
may be impaired with age, due to some depressive 
disorder and as a result of drug treatment, including 
some forms of antidepressant drug treatment. 
Fluoxetine is a commonly used antidepressant which 
acts by selectively inhibiting reuptake of 5HT.  Other 
SSRIs (selective serotonin reuptake inhibitors) are 
fluvoxamine, paroxetine, sertraline, citalopram, 
escitalopram. 
Fluoxetine is used as an antidepressant in endogenous 
depression and SSRIs are the first choice drugs because 
of their tolerability and safety. They are also used in 
anxiety disorders& obsessive compulsive neurosis. 
Some patients who were taking SSRIs like fluoxetine 
complain of forgetfulness. Though some studies had 
shown that SSRIs like fluoxetine improves cognition 
and memory, there are few studies which actually 
showed that cognition and memory had declined. 
Cognitive and psychomotor dysfunctions are nothing 
but symptoms of depression and they will improve 
along with mood during effective drug therapy. Most of 
the patient with depression and anxiety will definitely 
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show impairment of memory and cognition. By striking 
at the root cause, fluoxetine had also improved memory 
and cognitive functions. In both the study groups, 
fluoxetine had not shown any impairment of memory 
and cognitive status. 
In our study, fluoxetine had produced statistically 
significant improvement and there was no deterioration 
of subset scores of Wechsler memory scale in both the 
age groups. This improvement is statistically significant 
when compared to the baseline score of the same group. 
These findings are significant and are of clinical 
importance. 
 A further study is therefore essential in patients of 
older age group with already pre-existing memory 
impairment, to assess the longterm outcome of 
fluoxetine on memory functions.  
CONCLUSION: 
During this study period of one month, there was no 
deterioration of memory functions, rather there was 
improvement in memory functions. So, final score of 
the cognitive parameters are because of the resultant 
activity of direct drug action and improvement in the 
underlying disease. Fluoxetine does not cause any 
memory impairment in both age groups who do not 
suffer from any pre-existing conditions affecting 
memory. 
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